Alcoholic liver disease in relation to cancer incidence and mortality: Findings from a large, matched cohort study in South Korea

Tran, Thi Phuong Thao; Han, Minji; Luu, Ngoc Minh; Oh, Jin Kyoung

doi:10.1002/cam4.5614

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the finding from the long‐term follow‐up duration is more likely attributed to the pharmacological mechanisms of SGLT‐2i. Compared to DPP‐4i, the prolonged use of SGLT‐2i leads to weight reduction, which may potentially lower the risk of cancer 4,6,9,52–56 . Due to limitations in the database, the present study cannot examine whether the risk of incident cancer decreases with the duration of SGLT‐2i use.…”

Section: Discussionmentioning

confidence: 94%

Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study

Sung,

Hung,

Tung

et al. 2024

Diabetes Metabolism Res

View full text Add to dashboard Cite

AimsSodium‐glucose cotransporter 2 inhibitors (SGLT‐2is) have been demonstrated to be associated with cancer cell mechanisms. However, whether they increase the risk of cancer remains unclear. Thus, this study aimed to determine the association between SGLT‐2i use and the incidence of cancer in patients with diabetes mellitus (DM) in Taiwan.Materials and MethodsThis retrospective cohort study was based on the Taiwan National Health Insurance database. The study population comprised patients with DM, and those who first used SGLT‐2is during 2016–2018 were assigned to the study group. Greedy propensity score matching was performed to select patients who first used dipeptidyl peptidase 4 inhibitors (DPP‐4is), and these patients were assigned to the control group. A Cox proportional hazards model was used to estimate the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for cancer risk in the study and control groups; this model was adjusted for demographic characteristics, DM severity, comorbidities and concomitant medication use.ResultsAfter controlling for relevant variables, the SGLT‐2i cohort (aHR = 0.90, 95% CI = 0.87–0.93) had a significantly lower risk of developing cancer than the DPP‐4i cohort, particularly when the SGLT‐2i was dapagliflozin (aHR = 0.91, 95% CI = 0.87–0.95) or empagliflozin (aHR = 0.90, 95% CI = 0.86–0.94). Regarding cancer type, the SGLT‐2i cohort's risk of cancer was significantly lower than that of the DPP‐4i cohort for leukaemia, oesophageal, colorectal, liver, pancreatic, lung, skin and bladder cancer.ConclusionsSGLT‐2i use was associated with a significantly lower risk of cancer than DPP‐4i use.

show abstract

Section: Discussionmentioning

confidence: 94%